Association between recent pregnancy or ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Association between recent pregnancy or hormonal contraceptive exposure and outcome of desmoid-type fibromatosis.
Author(s) :
Debaudringhien, M. [Auteur]
Blay, Jean-Yves [Auteur]
Centre Léon Bérard [Lyon]
Bimbai, André-Michel [Auteur]
Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] [UNICANCER/Lille]
Bonvalot, Sylvie [Auteur]
Institut Curie [Paris]
Italiano, Antoine [Auteur]
Institut Bergonié [Bordeaux]
Rousset-Jablonski, Christine [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Corradini, Nadège [Auteur]
Centre Léon Bérard [Lyon]
Piperno-Neumann, Sophie [Auteur]
Institut Curie [Paris]
Chevreau, Christine [Auteur]
Institut Claudius Regaud [ICR]
Kurtz, Jean-Emmanuel [Auteur]
Centre Hospitalier Universitaire [Strasbourg] [CHU Strasbourg]
Guillemet, Cécile [Auteur]
Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen [CLCC Henri Becquerel]
Bompas, Emmanuelle [Auteur]
Institut de Cancérologie de l'Ouest [Angers/Nantes] [UNICANCER/ICO]
Collard, Olivier [Auteur]
Institut de Cancérologie de la Loire Lucien Neuwirth
Salas, Sebastien [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Le Cesne, Axel [Auteur]
Institut Gustave Roussy [IGR]
Orbach, Daniel [Auteur]
Institut Curie [Paris]
Thery, Julien [Auteur]
Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] [UNICANCER/Lille]
Le Deley, Marie-Cécile [Auteur]
Centre de recherche en épidémiologie et santé des populations [CESP]
Mir, Olivier [Auteur]
Institut Gustave Roussy [IGR]
Penel, Nicolas [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Blay, Jean-Yves [Auteur]
Centre Léon Bérard [Lyon]
Bimbai, André-Michel [Auteur]
Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] [UNICANCER/Lille]
Bonvalot, Sylvie [Auteur]
Institut Curie [Paris]
Italiano, Antoine [Auteur]
Institut Bergonié [Bordeaux]
Rousset-Jablonski, Christine [Auteur]
Centre Hospitalier Lyon Sud [CHU - HCL] [CHLS]
Corradini, Nadège [Auteur]
Centre Léon Bérard [Lyon]
Piperno-Neumann, Sophie [Auteur]
Institut Curie [Paris]
Chevreau, Christine [Auteur]
Institut Claudius Regaud [ICR]
Kurtz, Jean-Emmanuel [Auteur]
Centre Hospitalier Universitaire [Strasbourg] [CHU Strasbourg]
Guillemet, Cécile [Auteur]
Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen [CLCC Henri Becquerel]
Bompas, Emmanuelle [Auteur]
Institut de Cancérologie de l'Ouest [Angers/Nantes] [UNICANCER/ICO]
Collard, Olivier [Auteur]
Institut de Cancérologie de la Loire Lucien Neuwirth
Salas, Sebastien [Auteur]
Hôpital de la Timone [CHU - APHM] [TIMONE]
Le Cesne, Axel [Auteur]
Institut Gustave Roussy [IGR]
Orbach, Daniel [Auteur]
Institut Curie [Paris]
Thery, Julien [Auteur]
Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] [UNICANCER/Lille]
Le Deley, Marie-Cécile [Auteur]
Centre de recherche en épidémiologie et santé des populations [CESP]
Mir, Olivier [Auteur]
Institut Gustave Roussy [IGR]
Penel, Nicolas [Auteur]

METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Journal title :
European Society for Medical Oncology
Abbreviated title :
ESMO Open
Volume number :
7
Pages :
100578
Publication date :
2022-09-20
ISSN :
2059-7029
English keyword(s) :
desmoid-type fibromatosis
hormonal contraception
hormone-dependency tumor
outcome
pregnancy
hormonal contraception
hormone-dependency tumor
outcome
pregnancy
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
Background
The role of both hormonal contraception and pregnancy on the outcomes of desmoid-type fibromatosis (DF) is debatable.
Materials and methods
In the present study, we selected female patients of childbearing ...
Show more >Background The role of both hormonal contraception and pregnancy on the outcomes of desmoid-type fibromatosis (DF) is debatable. Materials and methods In the present study, we selected female patients of childbearing age from the prospective ALTITUDES cohort. The primary study endpoint was event-free survival (EFS), with an event defined as relapse or progression. We estimated the risk of events according to the use of hormonal contraception [estrogen–progestin (EP) and progestin] and pregnancy status using multivariate time-dependent models, controlling for major confounders. Results A total of 242 patients (median age, 34.7 years) were included in the present study. The abdominal wall was the most common tumor site (51%). Patients were managed by active surveillance (80%) or surgery (20%). Pregnancy occurred within 24 months before, at the time of, and after DF diagnosis in 33%, 5%, and 10% of the cases, respectively. Exposure to hormonal contraception was documented within 24 months before, at the time of, and after diagnosis in 44%, 34%, and 39% of the cases, respectively. The 2-year EFS was 75%. After adjusting for DF location, tumor size, front-line treatment strategy, and hormonal contraception, we observed an increased risk of events occurring at 24 months after pregnancy [hazard ratio (HR) = 2.09, P = 0.018]. We observed no statistically significant association between the risk of events and current EP exposure (HR = 1.28, P = 0.65), recent EP exposure (within 1-24 months, HR = 1.38, P = 0.39), current progestin exposure (HR = 0.81, P = 0.66), or recent progestin exposure (HR = 1.05, P = 0.91). Conclusions In our study, a recent history of pregnancy was associated with an increased risk of progression/relapse in patients with newly diagnosed DF, whereas hormonal contraception did not demonstrate an association with progression/relapse.Show less >
Show more >Background The role of both hormonal contraception and pregnancy on the outcomes of desmoid-type fibromatosis (DF) is debatable. Materials and methods In the present study, we selected female patients of childbearing age from the prospective ALTITUDES cohort. The primary study endpoint was event-free survival (EFS), with an event defined as relapse or progression. We estimated the risk of events according to the use of hormonal contraception [estrogen–progestin (EP) and progestin] and pregnancy status using multivariate time-dependent models, controlling for major confounders. Results A total of 242 patients (median age, 34.7 years) were included in the present study. The abdominal wall was the most common tumor site (51%). Patients were managed by active surveillance (80%) or surgery (20%). Pregnancy occurred within 24 months before, at the time of, and after DF diagnosis in 33%, 5%, and 10% of the cases, respectively. Exposure to hormonal contraception was documented within 24 months before, at the time of, and after diagnosis in 44%, 34%, and 39% of the cases, respectively. The 2-year EFS was 75%. After adjusting for DF location, tumor size, front-line treatment strategy, and hormonal contraception, we observed an increased risk of events occurring at 24 months after pregnancy [hazard ratio (HR) = 2.09, P = 0.018]. We observed no statistically significant association between the risk of events and current EP exposure (HR = 1.28, P = 0.65), recent EP exposure (within 1-24 months, HR = 1.38, P = 0.39), current progestin exposure (HR = 0.81, P = 0.66), or recent progestin exposure (HR = 1.05, P = 0.91). Conclusions In our study, a recent history of pregnancy was associated with an increased risk of progression/relapse in patients with newly diagnosed DF, whereas hormonal contraception did not demonstrate an association with progression/relapse.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
Université de Lille
CHU Lille
CHU Lille
Submission date :
2023-11-15T03:20:38Z
2024-05-13T13:23:00Z
2024-05-13T13:23:00Z
Files
- PIIS2059702922002083.pdf
- Non spécifié
- Open access
- Access the document
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States